Here is the design of a clinical trial:

Official Title: Heath Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitor Using Electronic Patient Reported Outcome in Daily Clinical Practice.

Included conditions:
- Renal Carcinoma Metastatic
- Kidney Neoplasms
- Renal Cancer

Study Armgroups:
- {'label': 'Electronic PRO', 'type': 'OTHER', 'description': 'All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.', 'interventionNames': ['Other: Electronic PRO in daily clinical practice']}

Interventions:
- {'type': 'OTHER', 'name': 'Electronic PRO in daily clinical practice', 'description': 'All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.', 'armGroupLabels': ['Electronic PRO']}

Primary Outcomes:
- {'measure': 'Rate of filled questionnaires at 12-months', 'description': 'Number of completed questionnaires compared to the number of consultations carried out during the first 12 months of follow-up.', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
One-sided α type I error rate of 0.05, statistical power of 0.90, 20% drop-out rate
Sample size
          The following hypotheses will be tested:
          H0 (null hypothesis for inefficiency): 60% or fewer patients having good compliance with REMOQOL during the first 12âmonths following the initiation of treatment will be considered as irrelevant;
          H1 (alternative efficiency hypothesis): 80% of patients having good compliance with REMOQOL during the first 12âmonths following the initiation of treatment is expected.
          Considering Flemingâs One-Stage design [32, 33] with a one-sided Î± type I error rate of 0.05 and a statistical power of 0.90, it will be necessary to include 45 evaluable patients. Due to an estimated 20% drop-out rate and non-evaluable patients, the overall number of patients included will be 56 (28 per treatment group).